Citations

Clear

3030 citation(s) found for "Susan, M".

Prediction of Opioid-Induced Respiratory Depression on Inpatient Wards Using Continuous Capnography and Oximetry: An International Prospective, Observational Trial
Uezono, Shoichi , Ti, Lian Kah , McIntyre, Robert C. , Tornero, Carlos , Dahan, Albert , Saager, Leif , Wittmann, Mária , Auckley, Dennis , Soto, Roy G. , Schramm, Frank, Ayad, Sabry , Kaw, Roop , Stefano, Paola Di, Moll, Vanessa , Dempsey, Susan J., Bühre, Wolfgang , Overdyk, Frank J. , Collaborators, on behalf of the PRediction of Opioid-induced respiratory Depression In patients monitored by capnoGraphY (PRODIGY) Group, Fiorda‐Diaz, Juan , Khanna, Ashish K. , Bergese, Sergio D. , Jungquist, Carla R. , Morimatsu, Hiroshi , Lee, Simon , Urman, Richard D , Weingarten, Toby N. , Brazzi, Luca , Guen, Morgan Le , Schramm, Frank, Sessler, Daniel I. , Uribe, Alberto A. , Collaborators, on behalf of the PRediction of Opioid-induced respiratory Depression In patients monitored by capnoGraphY (PRODIGY) Group, Law, Lawrence Siu‐Chun

Mayo Clinic

Anesthesia & Analgesia | April 18, 2020 | Volume: 131 | Issue: 4 | Pages: 1012-1024

10.1213/ane.0000000000004788 | PMID 32925318 Get It

BACKGROUND: Opioid-related adverse events are a serious problem in hospitalized patients. Little is known about patients who are likely to experience opioid-induced respiratory depression events on the general care floor and may benefit from improved monitoring and early intervention. The trial objective was to derive and validate a risk prediction tool for respiratory depression in patients receiving opioids, as detected by continuous pulse oximetry and capnography monitoring. METHODS: PRediction of Opioid-induced respiratory Depression In patients monitored by capnoGraphY (PRODIGY) was a prospective, observational trial of blinded continuous capnography and oximetry conducted at 16 sites in the United States, Europe, and Asia. Vital signs were intermittently monitored per standard of care. A total of 1335 patients receiving parenteral opioids and continuously monitored on the general care floor were included in the analysis. A respiratory depression episode was defined as respiratory rate ≤5 breaths/min (bpm), oxygen saturation ≤85%, or end-tidal carbon dioxide ≤15 or ≥60 mm Hg for ≥3 minutes; apnea episode lasting >30 seconds; or any respiratory opioid-related adverse event. A risk prediction tool was derived using a multivariable logistic regression model of 46 a priori defined risk factors with stepwise selection and was internally validated by bootstrapping. RESULTS: One or more respiratory depression episodes were detected in 614 (46%) of 1335 general care floor patients (43% male; mean age, 58 ± 14 years) continuously monitored for a median of 24 hours (interquartile range [IQR], 17–26). A multivariable respiratory depression prediction model with area under the curve of 0.740 was developed using 5 independent variables: age ≥60 (in decades), sex, opioid naivety, sleep disorders, and chronic heart failure. The PRODIGY risk prediction tool showed significant separation between patients with and without respiratory depression ( P < .001) and an odds ratio of 6.07 (95% confidence interval [CI], 4.44–8.30; P < .001) between the high- and low-risk groups. Compared to patients without respiratory depression episodes, mean hospital length of stay was 3 days longer in patients with ≥1 respiratory depression episode (10.5 ± 10.8 vs 7.7 ± 7.8 days; P < .0001) identified using continuous oximetry and capnography monitoring. CONCLUSIONS: A PRODIGY risk prediction model, derived from continuous oximetry and capnography, accurately predicts respiratory depression episodes in patients receiving opioids on the general care floor. Implementation of the PRODIGY score to determine the need for continuous monitoring may be a first step to reduce the incidence and consequences of respiratory compromise in patients receiving opioids on the general care floor.
Heat therapy reduces blood pressure and circulating endothelin‐1 levels, but does not improve walking performance or vascular function in patients with symptomatic peripheral artery disease
Monroe, Jacob C., Perkins, Susan M. , Yan, Han , Chen, Lin , Motaganahalli, Raghu L. , Roseguini, Bruno T.

Mayo Clinic

The FASEB Journal | April 17, 2020 | Volume: 34 | Issue: S1 | Pages: 1-1

10.1096/fasebj.2020.34.s1.03384 Get It

INTRODUCTION Patients with peripheral artery disease (PAD) are at a heightened risk of cardiovascular events and have markedly reduced vascular function and exercise tolerance. Heat therapy (HT) has emerged as a practical treatment to improve cardiovascular health in young individuals as well in patients with overt cardiovascular disease. We recently reported that a single 90 min session of HT applied to the legs of patients with PAD using water‐circulating trousers increases popliteal artery blood flow and reduces blood pressure and the circulating levels of the potent endogenous vasoconstrictor endothelin‐1 (ET‐1). The objective of the present study was to test the hypothesis that the repeated exposure to leg HT would lower blood pressure and ET‐1 levels and improve walking performance and conduit artery and cutaneous vascular function in patients with symptomatic PAD. METHODS Thirty‐two patients with symptomatic PAD (Age: 68± 8 years; Ankle‐brachial index: 0.67 ± 0.1) were assigned using a balanced randomized design to undergo 90 min of HT (48°C) or a thermoneutral treatment (33°C) 3 times per week for 6 consecutive weeks. The following outcomes were assessed at baseline and 3 and 6 weeks after the intervention: 1) resting ankle‐brachial index, 2) post‐occlusive reactive hyperemia in the popliteal artery (phase contrast magnetic resonance imaging), 3) leg cutaneous thermal hyperemia (laser Doppler flowmetry), 4) resting blood pressure every 5 min for 70 min, 5) 6‐min walk distance and 6) serum levels of ET‐1 and total nitrate (NOx). RESULTS Participants completed 17.7 ± 0.6 treatment sessions, resulting in a compliance rate of 98.7%. In the group exposed to HT, systolic blood pressure (SBP) decreased from baseline by ~3 mmHg at 6 weeks, while in the control group SBP increased by ~1 mmHg. A significant group by time interaction was observed for the changes in SBP from baseline to 6 weeks ( p=0.0049) with significant group differences at 20 min (Change in SBP: Control: 6.27 ± 15.5 vs. HT: −7.60 ± 13.6 mmHg, p=0.015 ) and 60 min (Change in SBP: Control: 4.13 ± 15.1 vs. HT: −7.33 ± 13.7 mmHg, p=0.0386 ). Similarly, serum ET‐1 levels decreased by ~15% from baseline to week 6 following exposure to HT, while a ~6% increase in this parameter occurred in the control group (Change in ET‐1: Control: 0.16 ± 0.6 vs. HT: −0.30 ± 0.4 pg/mL, p=0.035 – one outlier removed). Resting ABI, diastolic BP, 6MWT distance, hyperemic peak flow and cutaneous thermal hyperemia were not different between groups. CONCLUSION Exposure to repeated HT reduces systolic blood pressure and ET‐1 levels in patients with symptomatic PAD. These findings indicate that HT may be a practical and accessible nonpharmacological tool to reduce cardiovascular risk in PAD patients. Support or Funding Information American Heart Association Scientist Development grant (16SDG27600003).
Tumor mutational load predicts time to first treatment in chronic lymphocytic leukemia ( CLL ) and monoclonal B‐cell lymphocytosis beyond the CLL internat
Kleinstern, Geffen , O’Brien, Daniel R. , Tian, Shulan , Kabat, Brian, Rabe, Kari G. , Yan, Huihuang , Vachon, Celine M. , Call, Timothy G. , Bruins, Laura A., Campos, Cecília Bonolo de , Leis, José F., Shanafelt, Tait D. , Ding, Wei , Braggio, Esteban , Kabat, Brian F, Chaffee, Kari G. , Norman, Aaron D. , Boddicker, Nicholas J, Parikh, Sameer A , Bruins, Laura, Bonolo de Campos, Cecilia, Ding, Wei , Cerhan, James R , Shanafelt, Tait D , Braggio, Esteban , Li, Xing , Vachon, Celine M. , Boddicker, Nicholas , Parikh, Sameer A. , Cerhan, James R. , Kay, Neil E. , Slager, Susan L.

Mayo Clinic

American Journal of Hematology | April 12, 2020 | Volume: 95 | Issue: 8 | Pages: 906-917

10.1002/ajh.25831 | PMID 32279347 Get It

Abstract Next‐generation sequencing identified about 60 genes recurrently mutated in chronic lymphocytic leukemia (CLL). We examined the additive prognostic value of the total number of recurrently mutated CLL genes (i.e., tumor mutational load [TML]) or the individually mutated genes beyond the CLL international prognostic index (CLL‐IPI) in newly diagnosed CLL and high‐count monoclonal B‐cell lymphocytosis (HC MBL). We sequenced 59 genes among 557 individuals (112 HC MBL/445 CLL) in a multi‐stage design, to estimate hazard ratios (HR) and 95% confidence intervals (CI) for time‐to‐first treatment (TTT), adjusted for CLL‐IPI and sex. TML was associated with shorter TTT in the discovery and validation cohorts, with a combined estimate of continuous HR = 1.27 (CI:1.17‐1.39, P = 2.6 × 10 −8 ; c ‐statistic = 0.76). When stratified by CLL‐IPI, the association of TML with TTT was stronger and validated within low/intermediate risk (combined HR = 1.54, CI:1.37‐1.72, P = 7.0 × 10 −14 ). Overall, 80% of low/intermediate CLL‐IPI cases with two or more mutated genes progressed to require therapy within 5 years, compared to 24% among those without mutations. TML was also associated with shorter TTT in the HC MBL cohort (HR = 1.53, CI:1.12‐2.07, P = .007; c ‐statistic = 0.71). TML is a strong prognostic factor for TTT independent of CLL‐IPI, especially among low/intermediate CLL‐IPI risk, and a better predictor than any single gene. Mutational screening at early stages may improve risk stratification and better predict TTT.
Cholinergic neuroplasticity in asthma driven by TrkB signaling
Dragunas, Guilherme , Woest, Manon E., Nijboer, Susan, Bos, Sophie, Asselt, Janet, Groot, Anne P. de , Vohlídalová, Eva, Vermeulen, Corneel J., Ditz, Benedikt , Koppelman, Gerard H. , Berge, Maarten van den , Hacken, Nick H.T. ten , Timens, Wim , Munhoz, Carolina Demarchi , Prakash, Y. S. , Gosens, Reinoud , Kistemaker, Loes , Prakash, Y S , Gosens, Reinoud , Timens, Wim , Vermeulen, Cornelis Joseph , Vonk, Judith M.

Mayo Clinic

The FASEB Journal | April 11, 2020 | Volume: 34 | Issue: 6 | Pages: 7703-7717

10.1096/fj.202000170r | PMID 32277855 Get It

Abstract Parasympathetic neurons in the airways control bronchomotor tone. Increased activity of cholinergic neurons are mediators of airway hyperresponsiveness (AHR) in asthma, however, mechanisms are not elucidated. We describe remodeling of the cholinergic neuronal network in asthmatic airways driven by brain‐derived neurotrophic factor (BDNF) and Tropomyosin receptor kinase B ( TrkB). Human bronchial biopsies were stained for cholinergic marker vesicular acetylcholine transporter (VAChT). Human lung gene expression and single nucleotide polymorphisms (SNP) in neuroplasticity‐related genes were compared between asthma and healthy patients. Wild‐type (WT) and mutated TrkB knock‐in mice (Ntrk2tm1Ddg/J) with impaired BDNF signaling were chronically exposed to ovalbumin (OVA). Neuronal VAChT staining and airway narrowing in response to electrical field stimulation in precision cut lung slices (PCLS) were assessed. Increased cholinergic fibers in asthmatic airway biopsies was found, paralleled by increased TrkB gene expression in human lung tissue, and SNPs in the NTRK2 [TrkB] and BDNF genes linked to asthma. Chronic allergen exposure in mice resulted in increased density of cholinergic nerves, which was prevented by inhibiting TrkB. Increased nerve density resulted in AHR in vivo and in increased nerve‐dependent airway reactivity in lung slices mediated via TrkB. These findings show cholinergic neuroplasticity in asthma driven by TrkB signaling and suggest that the BDNF‐TrkB pathway may be a potential target.
Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report
Burroughs, Lauri M. , Petrović, Aleksandra , Brazauskas, Ruta , Liu, Xuerong , Griffith, Linda M. , Ochs, Hans D. , Bleesing, Jack , Edwards, Stephanie , Dvorak, Christopher C. , Chaudhury, Sonali , Prockop, Susan E. , Quinones, Ralph, Goldman, Frederick D. , Quigg, Troy C. , Chandrakasan, Shanmuganathan , Smith, Angela R. , Saldaña, Blachy J. Dávila , Thakar, Monica S. , Shenoy, Shalini , Forbes, Lisa R., Martinez, Caridad , Chellapandian, Deepak , Shereck, Evan , Miller, Holly, Kapoor, Neena , Barnum, Jessie L., Chong, Hey , Shyr, David C. , Chen, Karin , Shah, Ami J. , Weinacht, Katja G. , Joshi, Avni Y. , Gillio, Alfred P. , Cuvelier, Geoff D.E. , Keller, Michael D. , Rozmus, Jacob, Torgerson, Troy R. , Haddad, Élie , Sullivan, Kathleen E. , Logan, Brent R. , Puck, Jennifer M. , Pai, Sung‐Yun , Rawlings, David J. , Cowan, Morton J. , Satter, Lisa Forbes , Joshi, Avni, Cuvelier, Geoffrey D E , Forbes Satter, Lisa R , Prockop, Susan E , Dávila Saldaña, Blachy J , Dvorak, Christopher C , Haddad, Elie , Parikh, Suhag , Phelan, Rachel , Abu‐Arja, Rolla , Moore, Theodore Bruce , DeSantes, Kenneth B , Pulsipher, Michael A. , Kohn, Donald B. , Notarangelo, Luigi D , Chandrakasan, Shanmuganathan , Rozmus, Jacob , Shah, Ami J , Keller, Michael D

Mayo Clinic

Blood | April 8, 2020 | Volume: 135 | Issue: 23 | Pages: 2094-2105

10.1182/blood.2019002939 | PMID 32268350 Get It

Abstract Wiskott-Aldrich syndrome (WAS) is an X-linked disease caused by mutations in the WAS gene, leading to thrombocytopenia, eczema, recurrent infections, autoimmune disease, and malignancy. Hematopoietic cell transplantation (HCT) is the primary curative approach, with the goal of correcting the underlying immunodeficiency and thrombocytopenia. HCT outcomes have improved over time, particularly for patients with HLA-matched sibling and unrelated donors. We report the outcomes of 129 patients with WAS who underwent HCT at 29 Primary Immune Deficiency Treatment Consortium centers from 2005 through 2015. Median age at HCT was 1.2 years. Most patients (65%) received myeloablative busulfan-based conditioning. With a median follow-up of 4.5 years, the 5-year overall survival (OS) was 91%. Superior 5-year OS was observed in patients &lt;5 vs ≥5 years of age at the time of HCT (94% vs 66%; overall P = .0008). OS was excellent regardless of donor type, even in cord blood recipients (90%). Conditioning intensity did not affect OS, but was associated with donor T-cell and myeloid engraftment after HCT. Specifically, patients who received fludarabine/melphalan-based reduced-intensity regimens were more likely to have donor myeloid chimerism &lt;50% early after HCT. In addition, higher platelet counts were observed among recipients who achieved full (&gt;95%) vs low-level (5%-49%) donor myeloid engraftment. In summary, HCT outcomes for WAS have improved since 2005, compared with prior reports. HCT at a younger age continues to be associated with superior outcomes supporting the recommendation for early HCT. High-level donor myeloid engraftment is important for platelet reconstitution after either myeloablative or busulfan-containing reduced intensity conditioning. (This trial was registered at www.clinicaltrials.gov as #NCT02064933.)
Gender composition of speakers at two annual pain medicine meetings: a cross-sectional study
Moman, Rajat N. , Moeschler, Susan M. , Pearson, Amy CS, Hooten, W. Michael , Moman, Rajat , Pearson, Amy CS

Mayo Clinic

Regional Anesthesia & Pain Medicine | April 8, 2020 | Volume: 45 | Issue: 11 | Pages: 920-921

10.1136/rapm-2020-101353 | PMID 32269137 Get It

NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020
Pilarski, Robert , Yurgelun, Matthew B. , Dickson, Patricia , Elkhanany, Ahmed , Friedman, Susan , Hutton, Mollie L., Khan, Seema, Klein, Catherine, Kohlmann, Wendy , Kurian, Allison W. , Laronga, Christine , Mak, Julie , Menendez, Carolyn S. , Merajver, Sofía D. , Norquist, Barbara S., Offit, Kenneth , Pederson, Holly J. , Reiser, Gwen , Shannon, Kristen M. , Visvanathan, Kala , Weitzel, Jeffrey N. , Wick, Myra , Wisinski, Kari B. , Dwyer, Mary A., Darlow, Susan, Norquist, Barbara M. , Wick, Myra J, Weitzel, Jeffrey N , Visvanathan, Kala , Kurian, Allison W , Norquist, Barbara , Elkhanany, Ahmed , Daly, Mary Beryl , Berry, Michael P., Buys, Saundra S. , Domchek, Susan M. , Garber, Judy E. , Goggins, Michael , Litton, Jennifer K. , Pal, Tuya

Mayo Clinic

Journal of the National Comprehensive Cancer Network | April 7, 2020 | Volume: 18 | Issue: 4 | Pages: 380-391

10.6004/jnccn.2020.0017 | PMID 32259785 Get It

The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic provide recommendations for genetic testing and counseling for hereditary cancer syndromes, and risk management recommendations for patients who are diagnosed with syndromes associated with an increased risk of these cancers. The NCCN panel meets at least annually to review comments, examine relevant new data, and reevaluate and update recommendations. These NCCN Guidelines Insights summarize the panel’s discussion and most recent recommendations regarding criteria for high-penetrance genes associated with breast and ovarian cancer beyond BRCA1/2 , pancreas screening and genes associated with pancreatic cancer, genetic testing for the purpose of systemic therapy decision-making, and testing for people with Ashkenazi Jewish ancestry.
Coronary Disease Surveillance in the Community: Angiography and Revascularization
Gerber, Yariv , Gibbons, Raymond J. , Weston, Susan A., Fabbri, Matteo, Herrmann, Joerg , Manemann, Sheila M., Frye, Robert L. , Greason, Kevin L. , Killian, Jill M. , Roger, Véronique L. , Asleh, Rabea , Greason, Kevin

Mayo Clinic

Journal of the American Heart Association | April 2, 2020 | Volume: 9 | Issue: 7 | Pages: No page available

10.1161/jaha.119.015231 | PMID 32237975 Get It

Background Temporal declines in cardiac stress tests results, coronary revascularization, and cardiovascular mortality have suggested a decline in the population burden of coronary disease until the 2000s. However, recent data indicate these favorable trends could be ending. We aimed to assess the evolution of the population burden of coronary disease in the community by examining trends in angiography and revascularization. Methods and Results We analyzed age‐ and sex‐adjusted trends from all coronary angiographic diagnostic procedures and revascularizations performed in Olmsted County, MN from 2000 to 2018. A total of 12 981 invasive angiograms were performed among 9049 individuals (64% men; 55% aged ≥65 years). Adjusted angiography rates decreased by 30% (95% CI , 25%–34%) between 2000 and 2009 and leveled off thereafter. Including computed tomography, angiography uncovered an increase in angiography use in recent years (risk ratio=1.15 [95% CI , 1.07–1.23] for 2018 versus 2014) and a decline in the prevalence of anatomic CAD from 2000 to 2018. CAD severity declined substantially from 2000 to 2009, followed by a plateau. Among 6570 revascularizations (72% men; 57% aged ≥65 years), 77% were percutaneous coronary interventions and 23% coronary artery bypass graft surgeries. The adjusted revascularization rates declined by 34% (95% CI , 27%–39%) from 2000 to 2009, followed by a plateau (risk ratio=1.10 [95% CI , 1.00–1.22]). Conclusions Between 2000 and 2018 in the community, coronary angiography use declined initially, leveled off, and then increased. Trends in CAD severity and revascularization use decreased then plateaued. The most recent trends are concerning as they suggest the burden of coronary disease is no longer declining. This warrants reinvigorated primary prevention and population surveillance.
Essential Role of Patient Blood Management in a Pandemic: A Call for Action
Shander, Aryeh , Goobie, Susan M. , Aapro, Matti , Bisbe, Elvira , Callum, Jeannie , Erhard, J., Faraoni, David , Farmer, Shannon L. , Федорова, Т. А. , Gombotz, H., Gross, Irwin, Guinn, Nicole R. , Hamdorf, Jeffrey M. , Isbister, James P. , Ji, Hongwen , Kor, Daryl J. , Kurz, Johann, Lasocki, Sigismond , Leahy, Michael F. , Lee, Cheuk‐Kwong, Lee, Jeong Jae , Louw, Vernon , Meier, Jens , Mezzacasa, Anna, Múñoz, Manuel , Ozawa, Sherri , Pavesi, Marco , Shander, Nina, Spiess, Bruce D. , Thomson, Jackie, Trentino, Kevin M. , Zenger, Christoph, Hofmann, Axel , Warner, Matthew A. , Pérez-Calatayud, Ángel Augusto , Cushing, Melissa M. , Dyer, Wayne Bruce , Frank, Steven M. , Froessler, Bernd , Haas, Thorsten , Javidroozi, Mazyar , Kim, Young‐Woo , Lee, Cheuk Kwong , Spahn, Donat R. , Zenger, Christoph

Mayo Clinic

Anesthesia & Analgesia | April 2, 2020 | Volume: 131 | Issue: 1 | Pages: 74-85

10.1213/ane.0000000000004844 | PMID 32243296 Get It

The World Health Organization (WHO) has declared coronavirus disease 2019 (COVID-19), the disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a pandemic. Global health care now faces unprecedented challenges with widespread and rapid human-to-human transmission of SARS-CoV-2 and high morbidity and mortality with COVID-19 worldwide. Across the world, medical care is hampered by a critical shortage of not only hand sanitizers, personal protective equipment, ventilators, and hospital beds, but also impediments to the blood supply. Blood donation centers in many areas around the globe have mostly closed. Donors, practicing social distancing, some either with illness or undergoing self-quarantine, are quickly diminishing. Drastic public health initiatives have focused on containment and “flattening the curve” while invaluable resources are being depleted. In some countries, the point has been reached at which the demand for such resources, including donor blood, outstrips the supply. Questions as to the safety of blood persist. Although it does not appear very likely that the virus can be transmitted through allogeneic blood transfusion, this still remains to be fully determined. As options dwindle, we must enact regional and national shortage plans worldwide and more vitally disseminate the knowledge of and immediately implement patient blood management (PBM). PBM is an evidence-based bundle of care to optimize medical and surgical patient outcomes by clinically managing and preserving a patient’s own blood. This multinational and diverse group of authors issue this “Call to Action” underscoring “The Essential Role of Patient Blood Management in the Management of Pandemics” and urging all stakeholders and providers to implement the practical and commonsense principles of PBM and its multiprofessional and multimodality approaches.